Liver

Chronic Liver Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 12:37:01 +0000

Summary

Chronic Liver Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Chronic Liver Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Liver Disease, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases,...

$2,000.00

Acute Liver Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players

Wed, 13 Jul 2022 12:37:01 +0000

Summary

Acute Liver Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Acute Liver Failure pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Liver Failure, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, compa...

$2,000.00

Oxysterols Receptor LXR Alpha (Liver X Receptor Alpha or Nuclear Receptor Subfamily 1 Group H Member 3 or LXRA or NR1H3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

Tue, 12 Jul 2022 14:45:37 +0000

Summary

Oxysterols Receptor LXR Alpha (Liver X Receptor Alpha or Nuclear Receptor Subfamily 1 Group H Member 3 or LXRA or NR1H3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Oxysterols Receptor LXR Alpha (Liver X Receptor Alpha or Nuclear Receptor Subfamily 1 Group H Member 3 or LXRA or NR1H3) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Oxysterols Receptor LXR Alpha (Liver X Receptor Alpha or Nuclear Receptor Subfamily 1 Group H Member 3 or LXRA or NR1H3) targeted therapeutics develop...

$2,500.00

Non Alcoholic Fatty Liver Disease (NAFLD) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Fri, 08 Apr 2022 11:35:28 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD) (Gastrointestinal) pipeline landscape.

Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease. Nonalcoholic fatty liver disease is common and, for most people, causes no signs and symptoms and no complications. But in some people with nonalcoholic fatty liver disease, the fat that accumulates can cause inflammation and scarring in the liver. The most common symptoms that bring NAFLD to medical attention are malaise, fatigue, and right upper quadrant or diffuse abdominal discomfort.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non Alcoholic Fatty Liver Disease (NAFLD) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2...

$2,500.00

Liver Cirrhosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Fri, 08 Apr 2022 11:35:28 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape.

Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cirrhosis - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Liver Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug t...

$2,000.00

Fatty Liver Disease - Global Clinical Trials Review, H2, 2021

Fri, 03 Sep 2021 16:07:52 +0000

Summary

GlobalData's clinical trial report, “Fatty Liver Disease - Global Clinical Trials Review, H2, 2021" provides an overview of Fatty Liver Disease Clinical trials scenario. This report provides top line data relating to the clinical trials on Fatty Liver Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain co...

$2,500.00

Liver Fibrosis Disease - Global Clinical Trials Review, H2, 2020

Tue, 15 Dec 2020 12:29:33 +0000

Summary

GlobalData's clinical trial report, “Liver Fibrosis Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Liver Fibrosis Clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competiti...

$2,500.00

Chronic Pancreatitis – Pipeline Insight, 2020

Thu, 15 Oct 2020 14:02:56 +0000

DelveInsight’s, “Chronic Pancreatitis – Pipeline Insight, 2020,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Chronic Pancreatitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Chronic Pancreatitis Understanding Chronic Pancreatitis: Overview Chronic pancreatitis is an irreversible and progressive disorder of the pancreas characterized by inflammation, fibrosis, and scarring. Exocrine and endocrine functions are lost, often leading to chronic pain. The etiology is multifactorial, although alcoholism is the most significant risk factor in adults. The average age at diagnosis is 35 to 55 years. Chronic pancreatitis is a permanent, progressive destruction of pancreatic tissue and function. Clinical manifestations include disabling abdominal pain, steatorrhea, an...

$1,500.00

Primary Sclerosing Cholangitis– Pipeline Insight, 2020

Thu, 15 Oct 2020 12:43:30 +0000

This “Primary Sclerosing Cholangitis- Pipeline Insight, 2020” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Primary Sclerosing Cholangitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Primary Sclerosing Cholangitis Understanding Primary Sclerosing Cholangitis: Overview Primary sclerosing cholangitis (PSC) is characterized by inflammation in the bile ducts (cholangitis) that leads to scarring (sclerosis), narrowing of the ducts, and a buildup of bile in the liver. Early signs and symptoms include extreme tiredness, abdominal pain, and itchiness. As the condition worsens it may cause jaundice, an enlarged spleen, and eventually liver cirrhosis and failure. Other complications may include weight loss, vitamin deficiency, and osteoporosis. Many people with PSC de...

$2,000.00

Liver Transplant Rejection - Pipeline Review, H1 2020

Thu, 07 May 2020 13:39:47 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Transplant Rejection - Pipeline Review, H1 2020, provides an overview of the Liver Transplant Rejection (Immunology) pipeline landscape.

Liver transplantation is the conventional therapy used in various liver diseases. Liver has the unique ability to regenerate or grow, unlike any other organ in the body. Liver transplant replaces an injured or diseased liver with a healthy one. An entire liver or just a section may be transplanted. Following a transplant, the immune system may consider the transplanted liver as foreign and may work against it. Patients may hence develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously. These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights

Global Markets Direct's Pharmaceuti...

$2,000.00

Liver Failure (Hepatic Insufficiency) Global Clinical Trials Review, H1, 2020

Mon, 24 Feb 2020 15:56:48 +0000

Summary

GlobalData's clinical trial report, “Liver Failure (Hepatic Insufficiency) Global Clinical Trials Review, H1, 2020" provides an overview of Liver Failure (Hepatic Insufficiency) Clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Failure (Hepatic Insufficiency). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and ...

$2,500.00

Liver Transplant Rejection - Pipeline Review, H2 2019

Wed, 11 Dec 2019 11:38:48 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Transplant Rejection - Pipeline Review, H2 2019, provides an overview of the Liver Transplant Rejection (Immunology) pipeline landscape.

Liver transplantation is the conventional therapy used in various liver diseases. Liver has the unique ability to regenerate or grow, unlike any other organ in the body. Liver transplant replaces an injured or diseased liver with a healthy one. An entire liver or just a section may be transplanted. Following a transplant, the immune system may consider the transplanted liver as foreign and may work against it. Patients may hence develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously. These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights

Global Markets Direct's Pharmaceuti...

$2,000.00

Liver Cirrhosis - Pipeline Review, H1 2019

Tue, 26 Mar 2019 12:29:57 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H1 2019, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape.

Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and chronic alcohol abuse. The scar tissue damages the normal structure of the liver which affects the normal flow of blood through the liver. Symptoms include loss of appetite, itchy skin, weight loss, tiredness and weakness and nausea. Treatment includes liver transplant surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Cirrhosis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Liver Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological acti...

$2,000.00

Liver Transplant Rejection Global Clinical Trials Review, H2, 2017

Thu, 18 Jan 2018 13:06:38 +0000

Summary

GlobalData's clinical trial report, “Liver Transplant Rejection Global Clinical Trials Review, H2, 2017" provides an overview of Liver Transplant Rejection clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Transplant Rejection. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective count...

$2,500.00

Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2017

Thu, 18 Jan 2018 15:45:29 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2017, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape.

Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2017, provides comprehe...

$2,000.00

Liver Cirrhosis Global Clinical Trials Review, H2, 2017

Thu, 18 Jan 2018 13:06:38 +0000

Summary

GlobalData's clinical trial report, “Liver Cirrhosis Global Clinical Trials Review, H2, 2017" provides an overview of Liver Cirrhosis clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Cirrhosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive...

$2,500.00

Liver Diseases Global Clinical Trials Review, H2, 2017

Thu, 18 Jan 2018 13:06:38 +0000

Summary

GlobalData's clinical trial report, “Liver Diseases Global Clinical Trials Review, H2, 2017" provides an overview of Liver Diseases clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Diseases. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive ad...

$2,500.00

Liver Fibrosis Global Clinical Trials Review, H2, 2017

Thu, 18 Jan 2018 13:06:38 +0000

Summary

GlobalData's clinical trial report, “Liver Fibrosis Global Clinical Trials Review, H2, 2017" provides an overview of Liver Fibrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Liver Fibrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive ad...

$2,500.00

Epiomic Epidemiology Series: Non-Alcoholic Fatty Liver Disease (NAFLD) Forecast in 11 Major Markets 2017-2027

Mon, 12 Jun 2017 15:35:40 +0000

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Non-Alcoholic Fatty Liver Disease (NAFLD) in 11 Major Markets Non-alcoholic fatty liver disease (NAFLD) is the presence of hepatic steatosis in the absence of competing liver disease. It is a spectrum of liver disorders associated with steatosis, with no evidence of significant alcohol consumption. NAFLD develops in four main stages; Steatosis (simple fatty liver), Non-alcoholic steatohepatitis (NASH), Fibrosis and Cirrhosis. Non-alcoholic steatohepatitis (NASH) is a more serious form of steatosis, due to the added inflammation. It is defined as the presence of hepatic steatosis and inflammation with hepatocyte injury (ballooning) with or without fibrosis. This can progress to cirrhosis, liver failure and, more rarely, hepatocellular carcinoma. This report provides the current prevalent population for Non-alcoholic fatty liver disease (NAFLD) across 11 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Japan, Brazil, India and China) split by gender and 5-year age cohort. Along with the current preval...

$5,800.00

Liver Transplant Rejection - Pipeline Review, H1 2017

Thu, 04 May 2017 14:38:55 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Transplant Rejection – Pipeline Review, H1 2017, provides an overview of the Liver Transplant Rejection (Immunology) pipeline landscape.

Liver transplantation is the conventional therapy used in various liver diseases. Liver has the unique ability to regenerate or grow, unlike any other organ in the body. Liver transplant replaces an injured or diseased liver with a healthy one. An entire liver or just a section may be transplanted. Following a transplant, the immune system may consider the transplanted liver as foreign and may work against it. Patients may hence develop complications and ultimately reject the new organ. Therefore, immunosuppressive drugs are administered simultaneously. These immunosuppressive drugs prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights

Global Markets Direct's Pha...

$2,000.00

Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products

Fri, 28 Apr 2017 10:35:57 +0000

Summary

Fatty liver disease (FLD) comprises a spectrum of chronic liver disorders characterized by excessive lipid accumulation in the liver (steatosis), which may lead to inflammation (steatohepatitis) and fibrosis. It has the potential to progress to end-stage liver diseases such as cirrhosis, liver cancer and liver failure, and is also associated with numerous complications and co-morbidities, including cardiovascular and metabolic diseases. FLD can be divided into non-alcoholic FLD (NAFLD) and alcoholic FLD (AFLD), depending on the patent’s history of alcohol use.

FLD is the most common chronic liver disease in the world, and its global prevalence has increased rapidly in the past several decades. The worldwide prevalence of FLD is estimated at 20–45% in the general population, and up to 90% in obese patients. There is a broad consensus to describe the condition as the hepatic manifestation of metabolic syndrome, and it is closely associated with obesity, diabetes and dyslipidemia. NAFLD has become the main driver of the rapid growth of FLD prevalence,...

$6,995.00

Liver Cirrhosis- Market Insights, Epidemiology and Market Forecast-2023

Tue, 25 Apr 2017 20:08:12 +0000

Note*: This report requires 7-10 business days to complete. DelveInsight’s Liver Cirrhosis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market trends of the Crohn’s disease for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Liver Cirrhosis forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Liver Cirrhosis till 2023. Key Coverage and Benefits • The report will help in developing business strategies by understanding the trends shaping and driving the global Liver Cirrhosis market. • Identifying patient populations in the global “Liver Cirrhosismarket to improve product design, pricing, and launch plans. • Organize sales and marketing efforts by identifying the best opportunities for Liver Cirrhosis therapeutics in each of the markets covered. • To underst...

$4,950.00

Liver Dialysis Equipment - Medical Devices Pipeline Assessment, 2017

Wed, 19 Apr 2017 14:23:15 +0000

Summary

GlobalData's Medical Devices sector report, “Liver Dialysis Equipment - Medical Devices Pipeline Assessment, 2017" provides an overview of Liver Dialysis Equipment currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Liver Dialysis Equipment pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Liver Dialysis Equipment under development
- The report r...

$2,500.00

Liver Failure (Hepatic Insufficiency) - Pipeline Review, H2 2016

Wed, 19 Apr 2017 12:43:26 +0000

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) – Pipeline Review, H2 2016, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape.

Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Failure (Hepatic Insufficiency) – Pipeline Review, H2 2016, provides comp...

$2,000.00

Liver Cancer - Pipeline Review, H2 2016

Fri, 07 Apr 2017 13:51:23 +0000

Table of Contents
Table of Contents 2
Introduction 10
Liver Cancer Overview 11
Therapeutics Development 12
Liver Cancer - Therapeutics under Development by Companies 14
Liver Cancer - Therapeutics under Investigation by Universities/Institutes 29
Liver Cancer - Pipeline Products Glance 32
Liver Cancer - Products under Development by Companies 35
Liver Cancer - Products under Investigation by Universities/Institutes 56
Liver Cancer - Companies Involved in Therapeutics Development 60
Liver Cancer - Therapeutics Assessment 245
Drug Profiles 277
Liver Cancer - Dormant Projects 1096
Liver Cancer - Discontinued Products 1116
Liver Cancer - Product Development Milestones 1120
Appendix 1133

List of Tables
Number of Products under Development for Liver Cancer, H2 2016 49
Number of Products under Development for Liver Cancer - Comparative Analysis, H2 2016 50
Number of Products under Development by Companies, H2 2016 51
Number of Products under Development by Companies, H2 2016 (Contd..1) 52
Number of Produc...

$2,500.00